2CBCB-NBOMe (NBOMe-TCB-2) is a compound indirectly derived from the phenethylamine series of

hallucinogen Hallucinogens are a large, diverse class of psychoactive drugs that can produce altered states of consciousness characterized by major alterations in thought, mood, and perception as well as other changes. Most hallucinogens can be categorize ...

s, which was discovered in 2007 at

Purdue University Purdue University is a public land-grant research university in West Lafayette, Indiana, and the flagship campus of the Purdue University system. The university was founded in 1869 after Lafayette businessman John Purdue donated land and mone ...

as part of the ongoing research program of the team led by David Nichols focusing on the mapping of the specific amino acid residues responsible for ligand binding to the 5HT_2A receptor. 2CBCB-NBOMe acts as a potent and selective agonist for the 5-HT_2A and 5-HT_2C receptors, with a Ki of 0.27 nM at the human 5-HT_2A receptor, a similar potency to other agonists such as

TCB-2 TCB-2 is a hallucinogen discovered in 2006 by Thomas McLean working in the lab of David Nichols at Purdue University. It is a conformationally-restricted derivative of the phenethylamine 2C-B, also a hallucinogen, and acts as a potent agonist ...

, NBOMe-2C-I and Bromo-DragonFLY.

Analogues and derivatives

Legality

United Kingdom

United States

2CBCB-NBOMe is a controlled substance in Vermont as of January 2016.

References

5-HT2A agonists 5-HT2C agonists 25-NB (psychedelics) Benzocyclobutenes Bromoarenes Designer drugs Psychedelic drugs {{hallucinogen-stub